Evidence map›Paper›PMID 24244580›Full record

ArticlePloS one2013

Identification of candidate children for maturity-onset diabetes of the young type 2 (MODY2) gene testing: a seven-item clinical flowchart (7-iF).

Michele Pinelli, Fabio Acquaviva, Fabrizio Barbetti, Elisabetta Caredda, Sergio Cocozza, Maurizio Delvecchio, Enza Mozzillo, Daniele Pirozzi, Francesco Prisco, Ivana Rabbone and 6 more

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. NGS Analysis Revealed Digenic HeterozygousDiagnostics (Basel, Switzerland) · 2021
    Article
  8. Review
  9. Treatment Options for MODY Patients: A Systematic Review of Literature.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  10. Review
  11. Review
  12. Article
  13. Maturity Onset Diabetes of the Young is Not Necessarily Associated with Autosomal Inheritance: Case Description of a De Novo HFN1A Mutation.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Article
  14. Review
  15. Article
  16. Undiagnosed MODY: Time for Action.Current diabetes reports · 2015
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michele PinelliDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
Fabio Acquaviva
Fabrizio Barbetti
Elisabetta Caredda
Sergio Cocozza
Maurizio Delvecchio
Enza Mozzillo
Daniele Pirozzi
Francesco Prisco
Ivana Rabbone
Lucia Sacchetti
Nadia Tinto
Sonia Toni
Stefano Zucchini
Dario Iafusco
Italian Study Group on Diabetes of the Italian Society of Pediatric Endocrinology and Diabetology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MODY2 is the most prevalent monogenic form of diabetes in Italy with an estimated prevalence of about 0.5-1.5%. MODY2 is potentially indistinguishable from other forms of diabetes, however, its identification impacts on patients' quality of life and healthcare resources. Unfortunately, DNA direct sequencing as diagnostic test is not readily accessible and expensive. In addition current guidelines, aiming to establish when the test should be performed, proved a poor detection rate. Aim of this study is to propose a reliable and easy-to-use tool to identify candidate patients for MODY2 genetic testing. We designed and validated a diagnostic flowchart in the attempt to improve the detection rate and to increase the number of properly requested tests. The flowchart, called 7-iF, consists of 7 binary "yes or no" questions and its unequivocal output is an indication for whether testing or not. We tested the 7-iF to estimate its clinical utility in comparison to the clinical suspicion alone. The 7-iF, in a prospective 2-year study (921 diabetic children) showed a precision of about the 76%. Using retrospective data, the 7-iF showed a precision in identifying MODY2 patients of about 80% compared to the 40% of the clinical suspicion. On the other hand, despite a relatively high number of missing MODY2 patients, the 7-iF would not suggest the test for 90% of the non-MODY2 patients, demonstrating that a wide application of this method might 1) help less experienced clinicians in suspecting MODY2 patients and 2) reducing the number of unnecessary tests. With the 7-iF, a clinician can feel confident of identifying a potential case of MODY2 and suggest the molecular test without fear of wasting time and money. A Qaly-type analysis estimated an increase in the patients' quality of life and savings for the health care system of about 9 million euros per year.

Indexed as

Surveys and QuestionnairesAge of OnsetChildChild, PreschoolCost-Benefit AnalysisDecision TreesDiabetes Mellitus, Type 2FemaleGenetic TestingGlucokinaseGlycated HemoglobinHumansItalyMutationProspective StudiesQuality of LifeGlucokinaseGlycated Hemoglobinhemoglobin A1c protein, human

Identifiers

PMID24244580
PMCPMC3823596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.